Xentria Inc. The Source of Innovative Solutions

Xentria will license its experimental pulmonary sarcoidosis drug to Meitheal Pharmaceuticals in a deal worth up to $680 million. Xentria, Inc. 8700 W. Bryn Mawr, Suite 600S Chicago, Illinois 60631. United States The sponsor address listed is the last reported by the sponsor to OOPD ... Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®. Launched by XENTRIA, INC. Jul 10, 2024. Xentria Inc. received the U.S. Food and Drug Administration's orphan drug designation for its experimental drug XTMAB-16 to treat an ... Xentria, Inc. Research summary. Study XTMAB-16-202 is a long term extension study that will be run at approximately 38 sites in the ... Xentria Inc., a Chicago-based biotech company, opened its new corporate headquarters in Lincoln Park this week. The company also secured a ... Xeris Pharmaceuticals (XERS) improves patient lives by developing and commercializing innovative, ready-to-use therapeutic medicine. Xentria, Inc. USA, MD, Baltimore. Feedback, Motor Sequence Learning, and Brain Connectivity. Motor Learning, Y, All, 18-40, University of South ... Operator of a biopharmaceutic company intended to develop drugs to help solve medical unmet needs through meaningful patient engagement and novel scientific ... View Xentria (www.xentria.com) location in Illinois, United States , revenue, industry and description. Find related and similar companies as well as ...